These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 24813751)

  • 1. State-mandated insurance coverage is associated with the approach to hydrosalpinges before IVF.
    Omurtag K; Grindler NM; Roehl KA; Bates GW; Beltsos AN; Odem RR; Jungheim ES
    Reprod Biomed Online; 2014 Jul; 29(1):131-5. PubMed ID: 24813751
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How members of the Society for Reproductive Endocrinology and Infertility and Society of Reproductive Surgeons evaluate, define, and manage hydrosalpinges.
    Omurtag K; Grindler NM; Roehl KA; Bates GW; Beltsos AN; Odem RR; Jungheim ES
    Fertil Steril; 2012 May; 97(5):1095-100.e1-2. PubMed ID: 22405598
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety and Assisted Reproductive Technology Outcomes of Hysteroscopic Tubal Microinserts Versus Laparoscopic Proximal Tubal Occlusion or Salpingectomy for Hydrosalpinges Treatment.
    Arora R; Shapiro H; Liu K; Arthur R; Cruickshank B; Sharma P; Glass K; Baratz A; Librach C; Greenblatt EM
    J Obstet Gynaecol Can; 2020 Jun; 42(6):779-786. PubMed ID: 32224160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of in vitro fertilization state mandates for third party insurance coverage in the United States: a review and critical assessment.
    Peipert BJ; Montoya MN; Bedrick BS; Seifer DB; Jain T
    Reprod Biol Endocrinol; 2022 Aug; 20(1):111. PubMed ID: 35927756
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hysteroscopic proximal tubal occlusion versus laparoscopic salpingectomy as a treatment for hydrosalpinges prior to IVF or ICSI: an RCT.
    Dreyer K; Lier MC; Emanuel MH; Twisk JW; Mol BW; Schats R; Hompes PG; Mijatovic V
    Hum Reprod; 2016 Sep; 31(9):2005-16. PubMed ID: 27209341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association of state insurance coverage mandates with assisted reproductive technology care discontinuation.
    Lee JC; DeSantis CE; Yartel AK; Kissin DM; Kawwass JF
    Am J Obstet Gynecol; 2023 Mar; 228(3):315.e1-315.e14. PubMed ID: 36368429
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydrosalpinx - Salpingostomy, salpingectomy or tubal occlusion.
    Ng KYB; Cheong Y
    Best Pract Res Clin Obstet Gynaecol; 2019 Aug; 59():41-47. PubMed ID: 30824209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. State insurance mandates and racial and ethnic inequities in assisted reproductive technology utilization.
    Korkidakis A; DeSantis C; Kissin D; Hacker M; Koniares K; Yartel A; Adashi E; Penzias A;
    Fertil Steril; 2024 Jan; 121(1):54-62. PubMed ID: 37775023
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ovarian Reserve and Assisted Reproductive Technique Outcomes After Laparoscopic Proximal Tubal Occlusion or Salpingectomy in Women with Hydrosalpinx Undergoing in Vitro Fertilization: A Randomized Controlled Trial.
    Vignarajan CP; Malhotra N; Singh N
    J Minim Invasive Gynecol; 2019; 26(6):1070-1075. PubMed ID: 30366115
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assisted reproductive technology use, embryo transfer practices, and birth outcomes after infertility insurance mandates: New Jersey and Connecticut.
    Crawford S; Boulet SL; Jamieson DJ; Stone C; Mullen J; Kissin DM
    Fertil Steril; 2016 Feb; 105(2):347-55. PubMed ID: 26515377
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intracytoplasmic sperm injection use in states with and without insurance coverage mandates for infertility treatment, United States, 2000-2015.
    Dieke AC; Mehta A; Kissin DM; Nangia AK; Warner L; Boulet SL
    Fertil Steril; 2018 Apr; 109(4):691-697. PubMed ID: 29580644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Surgical treatment for hydrosalpinx prior to in-vitro fertilization embryo transfer: a network meta-analysis.
    Tsiami A; Chaimani A; Mavridis D; Siskou M; Assimakopoulos E; Sotiriadis A
    Ultrasound Obstet Gynecol; 2016 Oct; 48(4):434-445. PubMed ID: 26922863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Do state insurance mandates alter ICSI utilization?
    Zagadailov P; Seifer DB; Shan H; Zarek SM; Hsu AL
    Reprod Biol Endocrinol; 2020 Apr; 18(1):33. PubMed ID: 32334609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The impact of insurance mandates on donor oocyte utilization: an analysis of 39,338 donor oocyte cycles from the Society for Assisted Reproductive Technology registry.
    George JS; Lee MS; Ashby RK; Goldman R; Ginsburg ES; Lanes A; Srouji SS
    Am J Obstet Gynecol; 2022 Dec; 227(6):877.e1-877.e11. PubMed ID: 35863456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Disparities in Assisted Reproductive Technology Utilization by Race and Ethnicity, United States, 2014: A Commentary.
    Dieke AC; Zhang Y; Kissin DM; Barfield WD; Boulet SL
    J Womens Health (Larchmt); 2017 Jun; 26(6):605-608. PubMed ID: 28586255
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Differences in ICSI utilization rates among states with insurance mandates for ART coverage.
    Zagadailov P; Cho KS; Seifer DB
    Reprod Biol Endocrinol; 2021 Nov; 19(1):174. PubMed ID: 34847941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of state insurance mandates on racial/ethnic disparities in the utilization and outcomes of donor oocyte-assisted reproductive technologies.
    Liao C; Kotlyar AM; Seifer DB
    Fertil Steril; 2023 Jul; 120(1):111-122. PubMed ID: 36871857
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnosis and treatment of diminished ovarian reserve in assisted reproductive technology cycles of women up to age 40 years: the role of insurance mandates.
    Butts SF; Ratcliffe S; Dokras A; Seifer DB
    Fertil Steril; 2013 Feb; 99(2):382-8. PubMed ID: 23102859
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro fertilization and multiple pregnancies: an evidence-based analysis.
    Medical Advisory Secretariat
    Ont Health Technol Assess Ser; 2006; 6(18):1-63. PubMed ID: 23074488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Surgical treatment for tubal disease in women due to undergo in vitro fertilisation.
    Johnson N; van Voorst S; Sowter MC; Strandell A; Mol BW
    Cochrane Database Syst Rev; 2010 Jan; 2010(1):CD002125. PubMed ID: 20091531
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.